Agios Pharmaceuticals Inc... (AGIO)
NASDAQ: AGIO
· Real-Time Price · USD
28.76
-0.38 (-1.30%)
At close: May 13, 2025, 9:48 AM
Agios Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| Product Revenue | 36.5M | 26.82M | 11.74M | 121.09M | 59.85M | 13.84M |
| Product Revenue Growth | +36.07% | +128.48% | -90.30% | +102.32% | +332.42% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 41.53M | 51.7M | 38.54M | 35.54M | 31.01M | 35.3M | 25.82M | 30.41M | 28.37M | 32.77M | 29.12M | 28.26M | 31.52M | 31.53M | 27.15M | 29.21M | 33.55M | 39.78M | 34.84M | 35.95M | 38.5M | 34.83M | 33.02M | 32.39M | 31.79M | 31.86M | 31.1M | 26.63M | 24.55M | 22.71M | 17.46M | 16.13M | 14.82M | 15.38M | 11.85M | 12.64M | 10.84M | 10.18M | 9.93M | 8.93M | 6.95M |
| Selling, General, and Administrative Revenue Growth | -19.67% | +34.15% | +8.44% | +14.58% | -12.15% | +36.72% | -15.08% | +7.20% | -13.44% | +12.53% | +3.04% | -10.32% | -0.04% | +16.12% | -7.06% | -12.92% | -15.66% | +14.17% | -3.09% | -6.62% | +10.53% | +5.50% | +1.94% | +1.88% | -0.21% | +2.42% | +16.79% | +8.48% | +8.09% | +30.10% | +8.23% | +8.82% | -3.62% | +29.74% | -6.25% | +16.67% | +6.43% | +2.57% | +11.18% | +28.40% | n/a |
| Research and Development Revenue | 72.74M | 82.81M | 72.45M | 75.81M | 67.27M | 76.09M | 81.84M | 68.89M | 67.3M | 70.3M | 64.97M | 74.52M | 70.12M | 73.3M | 64M | 62.01M | 57.67M | 95.74M | 89.56M | 90.92M | 91.26M | 106.25M | 101.67M | 107.39M | 95.58M | 93.81M | 82.56M | 86.73M | 78.22M | 77.22M | 72.92M | 79.82M | 62.73M | 64.68M | 60.64M | 50.8M | 44.04M | 36.93M | 36.03M | 36.42M | 32.44M |
| Research and Development Revenue Growth | -12.16% | +14.29% | -4.42% | +12.69% | -11.58% | -7.03% | +18.79% | +2.37% | -4.26% | +8.21% | -12.82% | +6.27% | -4.33% | +14.53% | +3.21% | +7.53% | -39.77% | +6.91% | -1.50% | -0.37% | -14.11% | +4.50% | -5.32% | +12.35% | +1.89% | +13.62% | -4.81% | +10.87% | +1.31% | +5.90% | -8.64% | +27.23% | -3.01% | +6.65% | +19.37% | +15.36% | +19.24% | +2.51% | -1.08% | +12.27% | n/a |